Cybec 400 Dosage/Direction for Use

Recommended Dose and Mode of Administration: Celecoxib capsule, at dosed up to 200 mg twice per day, can be taken with or without food.
As the cardiovascular (CV) risks of Celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Symptomatic treatment of osteoarthritis (OA): The usual recommended dose of Celecoxib is 200 mg administered as a single dose. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after 2 weeks, other therapeutic options should be considered.
Symptomatic treatment of rheumatoid arthritis (RA): The recommended dose of Celecoxib is 200 mg twice per day.
Ankylosing Spondylitis (AS): The recommended dose of Celecoxib 200 mg administered as a single dose. Some patients may benefit from a total daily dose of 400 mg.
Management of acute pain: The recommended dose of Celecoxib 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Treatment of primary dysmenorrhea: The recommended dose of Celecoxib 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Low back pain (LBP): The recommended dose of Celecoxib is 200 mg or 400 mg daily, administered as a 200 mg single dose, or as 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.
CYP2C9 poor metabolizers: Patients who are known, or suspected to be CYP2C9 poor metabolizers based on previous history/experience with other CYP2C9 substrates should be administered Celecoxib with caution. Consider starting treatment at half the lowest recommended dose.
Elderly: No dosage adjustment is generally necessary. However, for elderly patients weighing lower than 50 kg, it is advisable to initiate therapy at the lowest recommended dose.
Hepatic impairment: No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A).
Introduce Celecoxib at half the recommended dose in arthritis or pain patients with moderate hepatic impairment (Child-Pugh class B).
Patients with severe hepatic impairment (Child-Pugh class C) have not been studied.
Renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment.
Patients with severe renal impairment have not been studied.
Co-administration with fluconazole: Celecoxib should be introduced at half the recommended dose in patients receiving fluconazole, a CYP2C9 inhibitor. Caution is advised when co-administering Celecoxib with other CYP2C9 inhibitors.
Pediatric patients: Celecoxib has not been studied in subjects under 18 years of age.